Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab
Bevacizumab has a lower risk of treatment-related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year-old man with lung adenocarcinoma and childhood asthma...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184640/ |